Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PH-15 by VistaGen Therapeutics for Cognitive Impairment: Likelihood of Approval
PH-15 is under clinical development by VistaGen Therapeutics and currently in Phase II for Cognitive Impairment. According to GlobalData, Phase...
Fasedienol by VistaGen Therapeutics for Anxiety Disorders: Likelihood of Approval
Fasedienol is under clinical development by VistaGen Therapeutics and currently in Phase III for Anxiety Disorders. According to GlobalData, Phase...
Fasedienol by VistaGen Therapeutics for Social Anxiety Disorder (SAD/Social Phobia): Likelihood of Approval
Fasedienol is under clinical development by VistaGen Therapeutics and currently in Phase III for Social Anxiety Disorder (SAD/Social Phobia). According...
PH-284 by VistaGen Therapeutics for Cachexia: Likelihood of Approval
PH-284 is under clinical development by VistaGen Therapeutics and currently in Phase II for Cachexia. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of VistaGen Therapeutics's Itruvone?
Itruvone is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase II program in Major Depressive Disorder. According...
Risk adjusted net present value: What is the current valuation of VistaGen Therapeutics's AV-101?
AV-101 is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase II program in Major Depressive Disorder. According...